Company intelligence / Profile preview

Gavia BIO

Minneapolis/St. Paul area*, Minnesota, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Gavia BIO develops a novel antimicrobial peptide and hydrogel formulation aimed at treating chronic wounds, burns, and oral infections by targeting resistant bacterial pathogens. The company’s lead technology has not yet reached clinical trials but addresses significant unmet needs in combating antibiotic resistance. No published clinical results as of mid/late 2024.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Antimicrobial peptides (AMPs)hydrogel-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

DGL13K

Pre-clinical

Indications: Antibiotic-resistant bacterial infections

Partnerships

Not specified; likely academic partnership with University of Minnesota based on founder affiliation and university startup status.

Beyond the preview

Go deeper on Gavia BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gavia BIO.

Explore the full profile